---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007692"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:09:19.945292+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Protalix Q1 net loss $4.6M; PRX-115 phase I positive, adds cohort

## Summary
- Revenue from goods $3.7M (-27% YoY); license/R&D services $0.1M (-98%) as Elfabrio obligations completed.
- Net loss $4.6M ($0.06/shr) vs $3.1M loss ($0.05) YoY; cash $48.5M at quarter end.
- PRX-115 phase I: dose-dependent uric acid reduction, well-tolerated; expanding to 8th cohort, planning phase II.
- R&D expenses down 50% to $2.9M on completion of Fabry program and Elfabrio regulatory filings.

## SEC filing metadata
- accession: 0001558370-24-007692
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837024007692/0001558370-24-007692-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837024007692/plx-20240510x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007692
- JSON: https://secwatch.observer/filing/0001558370-24-007692.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007692.txt

## Key facts
- Earnings Releases
  Protalix BioTherapeutics, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000155837024007692/0001558370-24-007692-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.